Opioid agonist therapy

We thank Srivastava and colleagues for their comprehensive review of the available treatments for opioid use disorder in the March issue of Canadian Family Physician, and for emphasizing the importance of accessibility of pharmacotherapy in the primary care setting.1 As they noted, opioid use disorder has a considerable public health effect in terms of morbidity and mortality, and it is essential that eligible patients are offered opioid agonist therapy, given the high risk of relapse and overdose associated with abstinence-based treatment